

Psoriatic arthritis – change, recommencement or demonstration of response authority application

When to use this form

Use this form to apply for **changing** or **recommencing** PBS-subsidised biological medicines for patients 18 years or over with severe psoriatic arthritis.

This form can also be used for **demonstrating a response** to the current PBS-subsidised treatment before temporarily stopping treatment.

Important information

Authority applications must be in writing and must include sufficient information to determine the patient's eligibility according to the PBS criteria.

Applications for **balance of supply** can be made in real time using the **Online PBS Authorities** system or by phone. Call 1800 700 270 Monday to Friday, 8 am to 5 pm, local time.

Under no circumstances will phone approvals be granted for psoriatic arthritis **change** or **recommencement** authority applications.

Where the term 'biological medicine' appears, it refers to adalimumab, bimekizumab, certolizumab pegol, etanercept, golimumab, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, tofacitinib, upadacitinib and ustekinumab.

The information in this form is correct at the time of publishing and may be subject to change.

Continuing treatment

This form is **ONLY** for **changing** or **recommencing** treatment or **demonstrating a response** to treatment before temporarily stopping treatment.

The patient remains eligible to receive **continuing** treatment providing they continue to sustain a response to treatment.

After a written authority application for the **first continuing** treatment has been approved, **subsequent continuing** treatments with PBS-subsidised biosimilar brands of biological medicines are **Authority Required (STREAMLINED)** and do not require authority approval from Services Australia for the listed quantity and repeats.

Section 100 arrangements for infliximab i.v.

This item is available to a patient who is attending:

- an approved private hospital, **or**
- a public hospital

and is a:

- day admitted patient
- non-admitted patient, **or**
- patient on discharge.

This item is not available as a PBS benefit for in-patients of a public hospital.

The hospital name and provider number must be included in this authority form.

Treatment specifics

The assessment of the patient's response to the course of treatment must be conducted within the time frame specified in the restriction. Where a demonstration of response is not conducted within the required time frame, the patient will be deemed to have failed treatment with that particular PBS-subsidised biological medicine.

A patient who has experienced a serious adverse reaction of a severity necessitating permanent treatment withdrawal is not considered to have failed treatment with that PBS-subsidised biological medicine.

For more information

Go to servicesaustralia.gov.au/healthprofessionals

medicare



Psoriatic arthritis – change, recommencement or demonstration of response authority application

Patient's details

1 Medicare card number

or

Department of Veterans' Affairs card number

2 Dr ☐ Mr ☐ Mrs ☐ Miss ☐ Ms ☐ Other

Family name

First given name

3 Date of birth (DD MM YYYY)

4 Patient's weight

 kg

Prescriber's details

5 Prescriber number

6 Dr ☐ Mr ☐ Mrs ☐ Miss ☐ Ms ☐ Other

Family name

First given name

7 Business phone number (including area code)

Alternative phone number (including area code)

Hospital details

8 Hospital name

This hospital is a:

☐ public hospital

☐ private hospital

9 Hospital provider number

Conditions and criteria

To qualify for PBS authority approval, the following conditions must be met.

10 The patient is being treated by a:

☐ rheumatologist

☐ clinical immunologist with expertise in the management of psoriatic arthritis.

11 Most recent biological medicine

Dates of the most recent treatment course

From (DD MM YYYY)

To (DD MM YYYY)

12 This application is for:

☐ adalimumab

☐ ixekizumab

☐ bimekizumab

☐ risankizumab

☐ certolizumab pegol

☐ secukinumab

☐ etanercept

☐ tofacitinib

☐ golimumab

☐ upadacitinib

☐ guselkumab

☐ ustekinumab

☐ infliximab i.v.

► Go to 14

or

☐ infliximab s.c. with i.v. loading

► Go to 13

or

☐ **demonstrating a response** to the current PBS-subsidised treatment before temporarily stopping treatment with this biological medicine

Demonstration of response can be submitted when recommending treatment.

► Go to 17

13 The patient is:

☐ **changing** from an alternate PBS-subsidised biological medicine, and an authority prescription for at least 2 i.v. doses of infliximab at weeks 0 and 2 is attached

or

☐ **recommencing** PBS-subsidised infliximab after a treatment break and an authority prescription for 1 i.v. dose of infliximab at week 0 is attached.



MCA0PB260 2503

14 The patient:

- ☐ is **changing** PBS-subsidised biological treatment for this condition after a break **< 5 years** (including **no break**)

and

- ☐ will be submitting a new baseline

or

- ☐ will be using the previous baseline

► **Go to 15**

or

- ☐ is **recommencing** PBS-subsidised biological treatment for this condition after a break **< 5 years**:

and

- ☐ the demonstration of response from the time of cessation is provided with this application

or

- ☐ the demonstration of response was submitted to Services Australia at the time of treatment cessation

and

- ☐ will be submitting a new baseline

or

- ☐ will be using the previous baseline

► **Go to 15**

or

- ☐ is **recommencing** PBS-subsidised biological treatment for this condition after a break **> 5 years**

and

- ☐ has previously received PBS-subsidised treatment with a biological medicine for this condition

and

- ☐ has had a break in treatment of at least 5 years from the most recently approved PBS-subsidised biological medicine for this condition

and

- ☐ will be submitting a new baseline

► **Go to 18**

15 The patient:

- ☐ has received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle

and

- ☐ has not already failed, or ceased to respond to, PBS-subsidised treatment with this drug (the biological medicine this application is for) for this condition during the current treatment cycle

and

- ☐ has not already failed, or ceased to respond to, PBS-subsidised treatment with 3 biological medicines for this condition within this treatment cycle since **1 October 2021**.

16 The patient:

- ☐ has **failed** to demonstrate or sustain a response to the most recent PBS-subsidised biological medicine

or

- ☐ has experienced a **serious adverse reaction** of a severity necessitating permanent withdrawal of the most recent PBS-subsidised biological medicine.

Provide details of the treatment and adverse reaction

| |
|--|
| |
| |
| |
| |

or

- ☐ has **demonstrated or sustain an adequate response** to the most recent PBS-subsidised biological medicine.

| | |
|--|-------------------|
| If the patient is demonstrating a response | ► Go to 17 |
| If the patient is providing a new baseline | ► Go to 18 |
| If the patient is not demonstrating a response and is not providing a new baseline | ► Go to 19 |

**For a patient demonstrating a response
(to current or previous biological medicine)**

The response assessment should be conducted while still on treatment, but **no later than 4 weeks** following cessation of treatment.

17 The patient has demonstrated an adequate response to treatment evidenced by:

- ☐ an erythrocyte sedimentation rate (ESR) level ≤ 25 mm/hr or reduced by at least 20% from baseline

Current ESR level mm/hr

Date of test (DD MM YYYY)

and/or

- ☐ a C-reactive protein (CRP) level ≤ 15 mg/L or reduced by at least 20% from baseline

Current CRP level mg/L

Date of test (DD MM YYYY)

Where only one marker (ESR or CRP) has been provided at baseline, the same marker must be used for assessment for all continuing applications.

and

- ☐ where baseline is at least 20 active (swollen and tender) joints, a reduction by at least 50% from baseline

Current total active joint count

Date of assessment (DD MM YYYY)

or

- ☐ where a baseline is at least 4 major joints (elbow, wrist, knee, ankle, shoulder and/or hip), a reduction by at least 50% from baseline

Current major joint count

Date of assessment (DD MM YYYY)

► **Go to 19**

For a patient submitting a new baseline

18 The patient has:

- ☐ an elevated ESR > 25 mm/hr

Baseline ESR level mm/hr

Date of test (DD MM YYYY)

and/or

- ☐ an elevated CRP > 15 mg/L

Baseline CRP level mg/L

Date of test (DD MM YYYY)

or

- ☐ the requirement to demonstrate an elevated ESR or CRP could not be met due to

- ☐ treatment with prednisolone dosed at 7.5mg or higher daily (or equivalent)

or

- ☐ treatment with a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent)

or

- ☐ provide an acceptable reason the patient could not demonstrate an elevated ESR or CRP level

and

- ☐ a total active joint count of at least 20 active (swollen and tender) joints

Baseline total active joint count

Date of assessment (DD MM YYYY)

or

- ☐ at least 4 major active joints from elbow, wrist, knee, ankle, shoulder and/or hip

Baseline major joint count

Date of assessment (DD MM YYYY)

Where only one marker (ESR or CRP) has been provided at baseline, the same marker must be used for assessment for all continuing applications.

Where a patient has at least 4 active major joints and less than 20 total active joints at baseline, assessment of the major joints only will be used for all continuing applications.

All measurements of **new baseline** joint count, ESR and/or CRP must be **no more than 4 weeks old** at the time of application.

Checklist

- 19  The relevant attachments need to be provided with this form.

☐ Details of the proposed prescription(s).

Privacy notice

- 20 Personal information is protected by law (including the *Privacy Act 1988*) and is collected by Services Australia for the purposes of assessing and processing this authority application.

Personal information may be used by Services Australia, or given to other parties where the individual has agreed to this, or where it is required or authorised by law (including for the purpose of research or conducting investigations).

More information about the way in which Services Australia manages personal information, including our privacy policy, can be found at servicesaustralia.gov.au/privacypolicy

Prescriber's declaration

You do not need to **sign** the declaration if you complete this form using Adobe Acrobat Reader and return this form through Health Professional Online Services (HPOS) at servicesaustralia.gov.au/hpos

21 I declare that:

- I am aware that this patient must meet the criteria listed in the current Schedule of Pharmaceutical Benefits to be eligible for this medicine.
- I have informed the patient that their personal information (including health information) will be disclosed to Services Australia for the purposes of assessing and processing this authority application.
- I have provided details of the proposed prescription(s) and the relevant attachments as specified in the Pharmaceutical Benefits Scheme restriction.
- the information I have provided in this form is complete and correct.

I understand that:


- giving false or misleading information is a serious offence.

☐ I have read, understood and agree to the above.

Date (DD MM YYYY) (you **must** date this declaration)

| | | | | | | | | | |
|--|--|--|--|--|--|--|--|--|--|
| | | | | | | | | | |
|--|--|--|--|--|--|--|--|--|--|

Prescriber's signature (**only** required if returning by post)

| |
|---|
|  |
|---|

Returning this form

Return this form, details of the proposed prescription(s) and any relevant attachments:

- **online** (no signature required), upload through HPOS at servicesaustralia.gov.au/hpos
or
- by post (signature required) to
Services Australia
Complex Drugs Programs
Reply Paid 9826
HOBART TAS 7001